Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Omer Shvili who wrote (115)	11/7/1998 11:03:00 AM
From: Omer Shvili	Read Replies (1) \| Respond to of 1386

My mistake David, just read the 13G. Arkin said he does not plan to take over the company and I believe him. Besides, buying the entire company would take at least $200 million, and I don't think Agis will want to make such a big investment. Agis and Arkin have big ambitions. They are going in Teva's footsteps, entering the US generic market (like Teva, they bought a US company to do this). Arkin understands the pharmaceutical business quite well, and he understood PARS' huge potential and was attracted by the rock bottom prices (like all of us). He was smart enough to take advantage of a weak market, building a big position without moving the stock. Agis has a lot of experience in pharmaceuticals, and might be able to help in PARS' attempts to find a partner for HU211. However, since most of their business is in generics, I think most of their contacts are with companies in that field. But any help and experience is welcome. Don't forget, we have a lot of experience internally as well. Haim Aviv has more experience in biotech than anyone else in Israel. The rest of team doesn't lack experience either. Like I said before, I think we'll get a partner by late Q1 '99. Than we'll get the big expsure, that Geron received today. GERN has made a big breakthrough, but which is far from being commercially available. HU211, on the other hand is only 2-3 years from being on the market. Omer

To: Omer Shvili who wrote (115)	12/12/1998 5:55:00 PM
From: Don Walster	Respond to of 1386

Dear Omer: Thank you for your email in which you questioned some of the things in my recent post to Yosi s. This is intended to be a public apology for anything inaccurate or inoffensive that I may have said about you: "Dear Omer: Please accept my sincere apology for having said things that you may have misinterpreted. When I used the word hype, I did not mean to do so in a derogatory way. To check myself out I looked up the definition in the dictionary. It defines hype as "extravagant or intensive publicity promotion." I don't think there is anything wrong about the use of the word hype. The only criticism I have heard of the use of the word hype is when someone hypes a stock on a thread where it doesn't belong. With that I agree. Omer, the figures of speech that I used were only intended to describe your enthusiasm. Anyway, I am sincerely sorry if they offended you. They were only intended to be descriptive and not derogatory. With regard to the other thing I said, I am sorry if I failed to see your early warnings about the length of time it would take and the other risks involved. I accept the fact that they were there and that it was my oversight. Carried away by your enthusiasm at the time, I guess I wasn't looking for anything negative. Omer, I am grateful to you for your generous good advice, but most of all for our friendship, which I hope will not be marred by this unfortunate incident. Kindest regards, Don